Navigation Links
TCS Signs Deal With Singapore's Parkway Hospitals

New Delhi: India's leading IT firm Tata Consultancy Services (TCS) Tuesday announced a $6 million strategic partnership with Singapore-based //Parkway Hospitals to provide and implement a healthcare information management solution.

According to the deal, TCS will work with Parkway Hospitals to customize and enhance its Hospital Management Solution (HMS) as per its specific needs, a TCS release said.

Parkway Hospitals is one of Asia's leading healthcare organizations and it includes Gleneagles, Mount Elizabeth, East Shore Hospitals, Parkway Laboratory Services, Medi-Rad Associates as well as several clinics globally.

"The association between two leading industry players in the Asia-Pacific region will create greater value for the customers," Girija Pande, executive vice-president and regional director of TCS Asia Pacific.

Source-IANS
'"/>




Page: 1

Related medicine news :

1. Recognize Heart Attack Signs
2. Parents Should Look For Signs Of Children Becoming Overweight
3. Early Warning Signs Of Heart Disease
4. Warning Signs On Powered Baby Milk
5. Genetical Screening Can Detect Early Signs Of Multiple Sclerosis
6. MIOT Hospital Signs Agreement With German Healthcare Facility
7. Blue Cross Signs Up 110,000 Minnesotans For Part D Medicare Plans
8. Teenager Shows Signs Of Recovery after Receiving Massive Dose of Radiation
9. Ramdev Signs MOU With Jharkhand Govt To Set Up Ayurveda Hospital
10. Visual Signs Attuned To Reading Rather Than Writing
11. Complaints Of Memory Loss Could Be Signs Of Alzheimers disease
Post Your Comments:
(Date:7/9/2008)...aleate (Acepromazine) is on extended backorder fro...nd this preparation into Gourmeds™ (chewable...nsion in the most frequently prescribed strengths....r veterinary use only. , ... -- Commonly prescribed for both cats and dogs, A...
(Date:7/9/2008)...he Maltese healthcare system,will be the focus of ... the,world learn how the island nation,s healthcar...odel for the European Union to follow. Affiliated,...um to discuss the future,of healthcare and informa...tions., Four recognized experts in healthcare and...
(Date:7/9/2008)...mpany Provides Interoperable EHR Solution Capa...ROLLTON, Ga., July 9 /PRNewswire/ -- Greenway Medi...e National Health IT Week,s Capitol Hill,Technolog...ne 9, 2008. The,showcase marked one of the healthc...ime demonstrations of ambulatory software provider...
(Date:7/9/2008)...r Summer, LAUREL, Miss., July 9 /PRNewswire/ -- W...popular parking place for TV-watchers, Sanderson F...mer program to encourage,families to get healthy b..., Studies show that over the course of a year, ch... school or participating in any activity other,tha...
Breaking Medicine News(10 mins):Health News: Wedgewood Pharmacy Responds to Acepromazine Maleate Drug Shortage 2Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 2Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 3Health News:Greenway Medical Technologies Leads Ambulatory Interoperability Exchange 2Health News:Greenway Medical Technologies Leads Ambulatory Interoperability Exchange 3Health News:Greenway Medical Technologies Leads Ambulatory Interoperability Exchange 4Health News:Sanderson Farms Launches New Summer Program Encouraging Families to Get Healthy 2
...creased by 12% in six years, according to the char...are now diagnosed with the disease, 3,000 of those...elanomas in men is that they tend to occur more co...they are often on the lower leg and more noticeabl...
...nancy can increase a mother's risk of having a hyp...ere very anxious// in the last three months of pre.... Lead researcher Professor Vivette Glover, of Im... only applied to women who had extreme anxiety, an...
...n somebody is likely to have an epileptic seizure....enly and without warning and can lead to disabilit... la Pitie-Salpetriere, Paris, believe it may be po...res by carrying out an electroencephalogram (EEG)....
...than 100 years. And while most of the popular reme... the use of aspirin has increased. This powerful p...nt blood clots, and even reduce the risk of heart ...35 years since aspirin's potent anti-clotting effe...
Other Medicine News:
(Date:7/8/2008)...- McGraw-Hill Professional, a leading,global provi...d medical,communities, today announced the additio...its comprehensive online pharmacy education,resour... ). Through an alliance with,Doctor Evidence, deve...ical,studies, AccessPharmacy now provides in-conte...
(Date:7/7/2008)... Includes ANA598 and ANA773 Acting via In... Conference Call Today at 2:00 PM... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) ann...ation of the Toll-Like Receptor-7 (TLR7) mechanism...n preclinical pharmacology testing,and the results...
(Date:7/7/2008)...-- OrbusNeich today announced that data,presented ...e Society of,Interventional Cardiology demonstrate... outcomes when compared to drug-eluting stents., ...principal,investigator and a professor with the Fe...ology, Department of Clinical Medicine and Cardiov...
(Date:7/6/2008)...ing Authorization Application currently ...uly 7 /- Cell Therapeutics,...the publication of results from its,randomized pha...glumex,CT-2103) with gemcitabine or vinorelbine f...tients with previously untreated non-small cell,lu...
Breaking Medicine Technology:McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5APIC launches first national C difficile prevalence study 14826 1APIC launches first national C difficile prevalence study 14826 2Cato Study Finds Iran a Surprising Model for Kidney Markets 14823 1Cato Study Finds Iran a Surprising Model for Kidney Markets 14823 2NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 1573 1NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 1573 2Subterfuge counter surveillance and assassination 3A The bodys fight with cervical cancer 2560 1Subterfuge counter surveillance and assassination 3A The bodys fight with cervical cancer 2560 2
...007 - Affymax, Inc.,(Nasdaq:AFFY) today announced ... trials of Hematide(TM) in dialysis and,non-dialys... showed,that in treatment naive, non-dialysis pati...ed monthly at an appropriate dose.,Similarly, the ...three-times weekly Epoetin Alfa demonstrated that ...
...CytRx Corporation,(NASDAQ:CYTR) today announced th... exclusively licensed to its majority-owned,subsid...een,published in the April 2007 issue of peer-revi...technology was developed by RXi,Co-founder, Scient...chusetts Medical School (UMMS) Professor of Bioche...
Other Medicine Technology:Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 2Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
The BARDEX I.C. Catheter represents Bard's newest technology in providing protection against NUTI.
Used to provide bladder drainage by percutaneous placement of a Malecot catheter. Supplied sterile in peel-open packages. Intended for one-time use.
Surgisis ES is designed to provide enhanced strength for intraoperative applications. Supplied sterile in peel-open packages. Intended for single patient, one-time use.
Stratasis Urethral Sling is intended for implantation to reinforce soft tissues where weakness exists. Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: